Harvard Bioscience, Inc. (HBIO)

Harvard Bioscience, Inc. (HBIO) is a healthcare company (medical instruments & supplies) based in the United States. The share price is $9.08, up 1.91% on the day, which values the company at $41.52M. Price as of 18 Nov 2026, 10:06 UTC, from Yahoo Finance.

Key facts

Share price
$9.08+1.91% today
Market value
$41.52M
Forward P/E
17.1×
Funk Score
30/100
Against its own history
Well below its usual priceusual price $20.92
200-week average
$22.9760% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Harvard Bioscience, Inc. in more detail

HBIO trades at 17.1× next year's expected earnings, 0.5× sales. Measured against its own history, the price is 57% below what its usual multiples would imply ($20.92) — well below its usual price. It sits 60% below its 200-week average of $22.97.

Over the last five fiscal years Harvard Bioscience, Inc. has compounded revenue -3.3% a year, free cash flow -9.9% a year. Its Funk Score is 30 out of 100 (financial strength 1.2, profitability 1.2, growth 0.5, value 9.2, each out of 10).

Worth checking: Altman Z in the distress zone; Share count keeps rising.

Harvard Bioscience, Inc. (HBIO): questions and answers

What is HBIO's PEG ratio?

Harvard Bioscience, Inc.'s PEG ratio is 1.31 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Harvard Bioscience, Inc.'s market cap?

Harvard Bioscience, Inc. is valued at $41.52M at a share price of $9.08.

Is HBIO overvalued or undervalued?

Against its own history, HBIO is well below its usual price: the price is 57% below the $20.92 implied by the median multiples it has traded at (price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is HBIO above its 200-week moving average?

No. HBIO is 60.5% below its 200-week average of $22.97. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Harvard Bioscience, Inc. growing?

Over the last five fiscal years Harvard Bioscience, Inc.'s revenue grew -3.3% a year; over ten years revenue grew -2.2% a year.

Does HBIO pay a dividend?

Harvard Bioscience, Inc. does not currently pay a regular dividend.

Cite this page

Funkfolio, “Harvard Bioscience, Inc. (HBIO) stock: price, valuation and fundamentals”, data as of 18 November 2026. https://funkfolio.com/stock/HBIO

Underlying data: Yahoo Finance; company filings with the SEC.